Illumina (NASDAQ:ILMN) Director Keith Meister Sells 131,019 Shares of Stock

Illumina, Inc. (NASDAQ:ILMN) Director Keith Meister sold 131,019 shares of the company’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $225.51, for a total transaction of $29,546,094.69. Following the sale, the director directly owned 1,278,832 shares in the company, valued at $288,389,404.32. This represents a 9.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Illumina Stock Up 1.3%

Shares of ILMN opened at $227.69 on Friday. The company has a market capitalization of $34.38 billion, a P/E ratio of 42.48, a PEG ratio of 3.16 and a beta of 1.45. Illumina, Inc. has a one year low of $88.00 and a one year high of $231.81. The business’s 50 day simple moving average is $192.98 and its 200-day simple moving average is $155.18. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. The firm had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The business’s revenue was up 9.4% on a year-over-year basis. During the same period last year, the firm posted $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, sell-side analysts predict that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Canaccord Genuity Group lifted their price target on Illumina from $190.00 to $205.00 and gave the company a “hold” rating in a report on Monday, August 3rd. Stifel Nicolaus raised their price objective on shares of Illumina from $155.00 to $225.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Leerink Partners boosted their target price on shares of Illumina from $175.00 to $210.00 and gave the stock an “outperform” rating in a research note on Friday, July 17th. Guggenheim upped their target price on shares of Illumina from $200.00 to $226.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Finally, Royal Bank Of Canada increased their price target on shares of Illumina from $170.00 to $230.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $188.40.

Hedge Funds Weigh In On Illumina

Institutional investors have recently modified their holdings of the stock. Fiduciary Financial Advisors acquired a new stake in shares of Illumina in the 2nd quarter valued at approximately $26,000. Keating Financial Advisory Services Inc. acquired a new position in Illumina during the second quarter valued at approximately $32,000. Rakuten Securities Inc. acquired a new position in Illumina during the second quarter valued at approximately $33,000. Elyxium Wealth LLC bought a new stake in Illumina in the fourth quarter valued at approximately $25,000. Finally, TD Waterhouse Canada Inc. bought a new stake in Illumina in the fourth quarter valued at approximately $26,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.